ClinicalTrials.gg
CompletedNCT05008055CAPITALUpdated Dec 20, 2024Results posted

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 2 interventional study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, sponsored by AstraZeneca. Completed at 17 sites in 7 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-12-20.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Study summary

This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).

Read the detailed description

The study protocol follows a modular design. The study will investigate the safety and efficacy of capivasertib monotherapy in participants with R/R Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL).

02

Conditions studied

  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Keywords

  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Mantle Cell Lymphoma
  • Capivasertib monotherapy
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥ 18 years of age, at the time of signing the
  • performance status ≤ 2
  • > 6 months
  • Female participants must not be breast-feeding and must have a negative pregnancy test (serum) prior to start of dosing

Module 1 specific inclusion criteria:

Additional Inclusion Criteria for Cohort 1A (R/R FL):

  1. confirmed diagnosis of FL Grade 1, 2, or 3a as assessed by investigator or local pathologist
  2. Current need for systemic treatment based on the Investigator's opinion
  3. , progressed or refractory (defined as failure to achieve at least a partial response [PR]) after at least 2 prior systemic (including anti-CD20 monoclonal antibody [mAb] and an alkylating agent)
  4. Bi-dimensionally on cross sectional imaging by computed tomography (CT) or magnetic resonance imaging (MRI) with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis.

Additional Inclusion Criteria for Cohort 1B (R/R MZL):

  1. Histologically confirmed MZL including splenic, nodal, and extranodal subtypes as assessed by investigator or local pathologist
  2. Current need for systemic treatment based on the Investigator's opinion
  3. Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after at least 2 prior systemic lines of therapy (including at least one anti-CD20mAb directed regimen either as monotherapy or as chemoimmunotherapy; Helicobacter pylori eradication and radiation therapy alone will not be considered a systemic treatment regimen)
  4. Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis

Additional Inclusion Criteria for Cohort 1C (R/R MCL):

  1. Histologically confirmed MCL, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1, as assessed by investigator or local pathologist
  2. Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after at least 2 prior systemic lines of therapy
  3. Participants must have received as prior therapies

    Prior regimens must have included:

    • BTK inhibitor and
    • Anti-CD20mAb therapy
  4. Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis

Exclusion criteria

Exclusion Criteria:

  • Prior (other than the disease under study), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which the participant has been disease free for ≥ 2 years
  • With the exception of alopecia, any unresolved non-haematological toxicities from prior therapy ≥ Grade 2 at the time of starting study treatment
  • Known medically apparent central nervous system lymphoma or
  • Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values at screening:

    1. \< 1.0 × 10\^9/L; \< 0.75 × 10\^9/L in participants with known bone marrow involvement of malignant disease
    2. \< 75 × 10\^9/L; \< 50 × 10\^9/L in participants with known bone marrow involvement of malignant disease
    3. \< 50 mL/min per the Cockcroft and Gault formula
  • abnormalities of glucose metabolism as participants with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment and Glycosylated ≥ 8.0% (63.9 mmol/mol)
  • Prior treatment with any of the following:

    1. Any agents or study drugs from a previous clinical study within 5 half lives or 2 weeks from the first dose of capivasertib in this study
    2. Strong inhibitors or inducers of within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or drugs that are sensitive to inhibition of CYP3A4 within 1 week prior to the first dose of study treatment
    3. Prior allogenic Haematopoietic stem cell transplant () within 6 months from the first dose of capivasertib (patients > 6 months after allogenic HSCT are eligible in the absence of active and concomitant immune suppressive therapy). Prior cellular therapies (eg, Chimeric antigen receptor T therapy) and/or autologous HSCT within 3 months from the first dose of capivasertib
    4. Receipt of live, attenuated vaccine within 28 days before the first dose of study treatment(s)
    5. Participants who, due to other medical conditions /prior history /concomitant medications are, in the investigator's opinion, at a risk of a venous thromboembolism (VTE) and are not willing to accept the VTE prophylaxis, will be excluded. The initiation of an adequate VTE prophylaxis will be based on treating physician risk/benefit assessment and in agreement with the local management guidelines

Additional exclusion core criteria may apply, please refer to the protocol

Module 1 specific exclusion criteria:

  1. Follicular lymphoma grade 3B
  2. Known transformation to aggressive lymphoma, eg, large cell lymphoma
  3. Participants who, in the Investigator's opinion, require immediate cytoreductive therapy for disease control
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Capivasertib monotherapy

    Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.

    Drug: Capivasertib

Interventions

  • Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate is defined as the proportion of patients achieving either complete response (CR) or partial response (PR) according to the Lugano 2014 Classification for non-Hodgkin lymphoma (NHL) as assessed by blinded independent central review (BICR).

    Time frame: First dose until progression of disease [PD] or last evaluable assessment in the absence of progression or data cut-off date (21.6 Months)

Secondary outcomes

  1. Duration of Response

    Duration of response is defined as the time from the date of first documented response until date of documented progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause.

    Time frame: First documented response until date of documented progression or data-cut off date (21.6 Months)

  2. Progression-free Survival

    Progression-free survival is defined as the time from the date of first dose until documented disease progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy, received another anti lymphoma therapy, or clinically progressed prior to progression according to the Lugano 2014 Classification for NHL.

    Time frame: First dose until documented disease progression or data cut-off date (21.6 Months)

  3. Overall Survival (OS)

    Overall survival is defined as time from the date of first dose until the date of death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy or received another anti lymphoma therapy. Patients who had not died by the analysis DCO date were censored at their last known date of being alive before the DCO date. Patients who were known to be alive or dead after the DCO date were censored at the DCO date. Patients who were lost to follow-up were censored at the date when they were last known to have been alive.

    Time frame: First dose until data cut-off date (21.6 Months)

  4. Number of Patients With Adverse Events and Serious Adverse Events

    The safety and tolerability of the capivasertib treatment in each Cohort was assessed.

    Time frame: Screening (Day -28 to -1) until Post-treatment follow-up up to 30 days after last dose or long-term follow-up or study completion (Every 12 weeks until death or lost to follow-up, unless patient have withdrawn consent [up to 21.6 Months])

  5. Plasma Concentration of Capivasertib Overtime

    The plasma concentration of capivasertib when administered in patients in each Cohort was determined.

    Time frame: Cycle 1 (28-day treatment Cycle) Day 1 and on Cycle 1 Day 8, Cycle 1 Day 15 and Cycle 1 Day 22 (Pre-dose and post-dose)

07

Results

Posted Jun 20, 2024

Participant flow

The study was conducted from 3 November 2021 and analyses presented in this results form are based on a data cut-off of 22 August 2023.

Participant flow — Overall Study
MilestoneRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Started16410
Completed1339
Not completed311
Withdrew: Patients ongoing treatment at data cut-off date of 22 august 2023.311

Outcome measures

PrimaryObjective Response Rate

Objective response rate is defined as the proportion of patients achieving either complete response (CR) or partial response (PR) according to the Lugano 2014 Classification for non-Hodgkin lymphoma (NHL) as assessed by blinded independent central review (BICR).

Time frame:
First dose until progression of disease [PD] or last evaluable assessment in the absence of progression or data cut-off date (21.6 Months)
Reported as:
Number · Percentage of Patients
Objective Response Rate
Percentage of PatientsRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Objective Response Rate18.8 (4.0 to 45.6)33.3 (0.8 to 90.6)30.0 (6.7 to 65.2)
SecondaryDuration of Response

Duration of response is defined as the time from the date of first documented response until date of documented progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause.

Time frame:
First documented response until date of documented progression or data-cut off date (21.6 Months)
Reported as:
Median · Months
Duration of Response
MonthsRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Duration of Response1.9 (1.7 to NA)NA (NA to NA)1.9 (NA to NA)
SecondaryProgression-free Survival

Progression-free survival is defined as the time from the date of first dose until documented disease progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy, received another anti lymphoma therapy, or clinically progressed prior to progression according to the Lugano 2014 Classification for NHL.

Time frame:
First dose until documented disease progression or data cut-off date (21.6 Months)
Reported as:
Median · Months
Progression-free Survival
MonthsRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Progression-free Survival5.4 (3.4 to NA)NA (1.4 to NA)1.9 (0.9 to NA)
SecondaryOverall Survival (OS)

Overall survival is defined as time from the date of first dose until the date of death due to any cause. The analysis included all dosed patients, regardless of whether the patient withdrew from therapy or received another anti lymphoma therapy. Patients who had not died by the analysis DCO date were censored at their last known date of being alive before the DCO date. Patients who were known to be alive or dead after the DCO date were censored at the DCO date. Patients who were lost to follow-up were censored at the date when they were last known to have been alive.

Time frame:
First dose until data cut-off date (21.6 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Overall Survival (OS)NA (NA to NA)NA (1.4 to NA)NA (2.0 to NA)
SecondaryNumber of Patients With Adverse Events and Serious Adverse Events

The safety and tolerability of the capivasertib treatment in each Cohort was assessed.

Time frame:
Screening (Day -28 to -1) until Post-treatment follow-up up to 30 days after last dose or long-term follow-up or study completion (Every 12 weeks until death or lost to follow-up, unless patient have withdrawn consent [up to 21.6 Months])
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events and Serious Adverse Events
ParticipantsRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Any adverse event (AE)16310
Any AE possibly related to treatment1438
Any AE of CTCAE grade 3 or higher717
Any AE of CTCAE grade 3 or higher, possibly related to treatment315
Any AE with outcome = death000
Any AE with outcome = death, possibly related to treatment000
Any SAE (including events with outcome = death)203
Any SAE (including events with outcome = death), possibly related to treatment003
SecondaryPlasma Concentration of Capivasertib Overtime

The plasma concentration of capivasertib when administered in patients in each Cohort was determined.

Time frame:
Cycle 1 (28-day treatment Cycle) Day 1 and on Cycle 1 Day 8, Cycle 1 Day 15 and Cycle 1 Day 22 (Pre-dose and post-dose)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Capivasertib Overtime
ng/mLRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Cycle 1 Day 1 (Post-dose [1 hour])394.9 ± 157.0414.4 ± 125.7287.1 ± 676.2
Cycle 1 Day 1 (Post-dose [2 hours])883.7 ± 59.12962.9 ± 40.33976.1 ± 58.27
Cycle 1 Day 1 (Post-dose [4 hours])528.5 ± 49.28677.2 ± 65.77780.1 ± 56.99
Cycle 1 Day 8 (Pre-dose)6.149 ± 207.48.477 ± 103.914.31 ± 138.8
Cycle 1 Day 15 (Pre-dose)5.844 ± 146.19.245 ± 73.6332.36 ± 373.5
Cycle 1 Day 22 (Pre-dose)7.974 ± 372.2NA ± NANA ± NA

Adverse events

Collected over Screening (Day -28 to -1) until Post-treatment follow-up up to 30 days after last dose or long-term follow-up or study completion (Every 12 weeks until death or lost to follow-up, unless patient have withdrawn consent [up to 21.6 Months]). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib Monotherapy0/16 (0%)2/16 (12.5%)16/16 (100%)
Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib Monotherapy1/4 (25%)0/4 (0%)3/4 (75%)
Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy2/10 (20%)3/10 (30%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
Perirectal abscessInfections and infestations0/160/41/10
HyperglycaemiaMetabolism and nutrition disorders0/160/41/10
DiarrhoeaGastrointestinal disorders0/160/41/10
Erythema multiformeSkin and subcutaneous tissue disorders0/160/41/10
COVID-19 pneumoniaInfections and infestations1/160/40/10
Obliterative bronchiolitisRespiratory, thoracic and mediastinal disorders1/160/40/10
Most frequent other events
Showing 10 of 76
Most frequent other events
EventRelapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib Monotherapy
DiarrhoeaGastrointestinal disorders15/162/44/10
NauseaGastrointestinal disorders2/162/45/10
RashSkin and subcutaneous tissue disorders2/160/43/10
COVID-19Infections and infestations0/161/41/10
Respiratory tract infectionInfections and infestations0/161/40/10
AnaemiaBlood and lymphatic system disorders1/161/40/10
Decreased appetiteMetabolism and nutrition disorders2/161/41/10
HyperuricaemiaMetabolism and nutrition disorders0/161/42/10
HeadacheNervous system disorders3/161/40/10
Deep vein thrombosisVascular disorders0/161/40/10

Baseline characteristics

Safety analysis set included for baseline characteristics, and it included all patients who received any amount of study treatment.

Age, Continuous
Age, Continuous(Years)Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib MonotherapyTotal
Mean55.7 ± 12.0766.8 ± 4.9276.2 ± 9.7264.0 ± 14.06
Sex: Female, Male
Sex: Female, Male(Participants)Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib MonotherapyTotal
Female72413
Male92617
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib MonotherapyTotal
Asian5005
White103720
Other0112
Not reported1023
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Relapsed or Refractory Follicular Lymphoma (R/R FL): Capivasertib MonotherapyRelapsed or Refractory Marginal Zone Lymphoma (R/R MZL): Capivasertib MonotherapyRelapsed or Refractory Mantle Cell Lymphoma (R/R MCL): Capivasertib MonotherapyTotal
Hispanic or Latino3003
Not Hispanic or Latino124521
Missing0044
Other1012
08

Study locations

17 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Aarhus N, DK8200, Denmark
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Villejuif Cedex, 94805, France
  • Research Site
    Busan, 49241, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 3722, Korea, Republic of
  • Research Site
    Badalona, 08003, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patientlevel data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Aug 2023, 21 months.

Results were first posted in Jun 2024, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Aug 17, 2021
StartActual
Nov 3, 2021
Primary completionActual
Aug 22, 2023
CompletionActual
Oct 25, 2024
Results first posted
Jun 20, 2024
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05008055
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Aug 17, 2021
Start date
Nov 3, 2021
Primary completion
Aug 22, 2023
Completion
Oct 25, 2024
Results posted
Jun 20, 2024
Last update
Dec 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion